Activation of Akt signaling in prostate induces a TGFβ-mediated restraint on cancer progression and metastasis

Oncogene

Volumn 33, Issue 28, 2014, Pages 3660-3667

  Bjerke, G A ^a   Yang, C S ^a   Frierson, H F ^a   Paschal, B M ^a   Wotton, D ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Akt; prostate cancer; Pten; signaling; TGF

Indexed keywords

PROTEIN KINASE B; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA2;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; CORRELATIONAL STUDY; GENE DELETION; GENE EXPRESSION; HUMAN; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PTEN GENE; RECEPTOR GENE; TUMOR INVASION; TUMOR SUPPRESSOR GENE;

MUS;

ADENOCARCINOMA; ANIMALS; DISEASE PROGRESSION; EPITHELIAL CELLS; GENE DELETION; HOMOZYGOTE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MICE; NEOPLASM INVASIVENESS; PROSTATE; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84904250933     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.342     Document Type: Article

References (42)

1. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997; 57: 4997-5000. (Pubitemid 27498107)
2. Dahia PL. PTEN, a unique tumor suppressor gene. Endocr Relat Cancer 2000; 7: 115-129. (Pubitemid 30609989)
3. Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky D et al. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 1998; 58: 204-209. (Pubitemid 28047054)
4. Wang SI, Parsons R, Ittmann M. Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin Cancer Res 1998; 4: 811-815. (Pubitemid 28193582)
5. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000; 100: 387-390.
6. Yamada KM, Araki M. Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J Cell Sci 2001; 114(Part 13): 2375-2382. (Pubitemid 32684793)
7. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 1999; 96: 1563-1568. (Pubitemid 29098491)
8. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet 1998; 19: 348-355. (Pubitemid 28357906)
9. Ma X, Ziel-van der Made AC, Autar B, van der Korput HA, Vermeij M, van Duijn P et al. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res 2005; 65: 5730-5739. (Pubitemid 40911176)
10. Suzuki A, Yamaguchi MT, Ohteki T, Sasaki T, Kaisho T, Kimura Y et al. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 2001; 14: 523-534. (Pubitemid 32520864)
11. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A et al. Pten dose dictates cancer progression in the prostate. PLoS Biol 2003; 1: E59.
12. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003; 4: 209-221. (Pubitemid 37163835)
13. Bayascas JR, Leslie NR, Parsons R, Fleming S, Alessi DR. Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(/-) mice. Curr Biol 2005; 15: 1839-1846. (Pubitemid 41501519)
14. Chen ML, Xu PZ, Peng XD, Chen WS, Guzman G, Yang X et al. The deficiency of Akt1 is sufficient to suppress tumor development in Pten/- mice. Genes Dev 2006; 20: 1569-1574. (Pubitemid 43901096)
15. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004; 10: 594-601. (Pubitemid 38796850)
16. Majumder PK, Yeh JJ, George DJ, Febbo PG, Kum J, Xue Q et al. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci USA 2003; 100: 7841-7846. (Pubitemid 36760057)
17. Heldin C-H, Miyazono K, ten Dijke P. TGF- signalling from cell membrane to nucleus through SMAD proteins. Nature 1997; 390: 465-471. (Pubitemid 28013118)
18. MassaguéJ. TGF- signal transduction. Annu Rev Biochem 1998; 67: 753-791.
19. Zhang Y, Derynck R. Regulation of Smad signaling by protein associations and signaling crosstalk. Trends Cell Biol 1999; 9: 274-279. (Pubitemid 29305517)
20. Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev 2005; 19: 2783-2810. (Pubitemid 41739965)
21. Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer 2010; 10: 415-424.
22. Massague J, Blain SW, Lo RS. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 2000; 103: 295-309.
23. Levy L, Hill CS. Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 2006; 17: 41-58. (Pubitemid 43117515)
24. Aitchison AA, Veerakumarasivam A, Vias M, Kumar R, Hamdy FC, Neal DE et al. Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer. Prostate 2008; 68: 661-674. (Pubitemid 351614644)
25. Zhao H, Shiina H, Greene KL, Li LC, Tanaka Y, Kishi H et al. CpG methylation at promoter site -140 inactivates TGFbeta2 receptor gene in prostate cancer. Cancer 2005; 104: 44-52. (Pubitemid 40847751)
26. Guo Y, Jacobs SC, Kyprianou N. Down-regulation of protein and mRNA expression for transforming growth factor-beta (TGF-beta1) type I and type II receptors in human prostate cancer. Int J Cancer 1997; 71: 573-579. (Pubitemid 27239366)
27. Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Lang S, Kato M et al. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin Cancer Res 1996; 2: 1255-1261. (Pubitemid 26299422)
28. Williams RH, Stapleton AM, Yang G, Truong LD, Rogers E, Timme TL et al. Reduced levels of transforming growth factor beta receptor type II in human prostate cancer: an immunohistochemical study. Clin Cancer Res 1996; 2: 635-640. (Pubitemid 26135335)
29. Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011; 470: 269-273.
30. Ding Z, Wu CJ, Jaskelioff M, Ivanova E, Kost-Alimova M, Protopopov A et al. Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell 2012; 148: 896-907.
31. Chytil A, Magnuson MA, Wright CV, Moses HL. Conditional inactivation of the TGFbeta type II receptor using Cre:Lox. Genesis 2002; 32: 73-75. (Pubitemid 34211700)
32. Wu X, Wu J, Huang J, Powell WC, Zhang J, Matusik RJ et al. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev 2001; 101: 61-69. (Pubitemid 32186310)
33. Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004; 351: 1488-1490. (Pubitemid 39315314)
34. Majumder PK, Grisanzio C, OConnell F, Barry M, Brito JM, Xu Q et al. A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 2008; 14: 146-155.
35. Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C, Pandolfi PP. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 2001; 27: 222-224. (Pubitemid 32157454)
36. Kim J, Roh M, Doubinskaia I, Algarroba GN, Eltoum IE, Abdulkadir SA. A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53. Oncogene 2012; 31: 322-332.
37. Sorrentino A, Thakur N, Grimsby S, Marcusson A, von Bulow V, Schuster N et al. The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat Cell Biol 2008; 10: 1199-1207.
38. Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi I, Ueno N et al. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 1995; 270: 2008-2011. (Pubitemid 26097194)
39. Truett GE, Heeger P, Mynatt RL, Truett AA, Walker JA, Warman ML. Preparation of PCR-quality mouse genomic DNA with hot sodium hydroxide and tris (HotSHOT). Biotechniques 2000; 29: 52-54. (Pubitemid 30439416)
40. Bartholin L, Melhuish TA, Powers SE, Goddard-Leon S, Treilleux I, Sutherland AE et al. Maternal Tgif is required for vascularization of the embryonic placenta. Dev Biol 2008; 319: 285-297.
41. Galgano MT, Conaway M, Spencer AM, Paschal BM, Frierson Jr. HF. PRK1 distribution in normal tissues and carcinomas: overexpression and activation in ovarian serous carcinoma. Hum Pathol 2009; 40: 1434-1440.
42. Powers SE, Taniguchi K, Yen W, Melhuish TA, Shen J, Walsh CA et al. Tgif1 and Tgif2 regulate Nodal signaling and are required for gastrulation. Development 2010; 137: 249-259.